Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07035431

Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area

This study is intended to evaluate the safety and effectiveness of Sponge-based Endoscopic Vacuum Therapy (EVT) using Endo-SPONGE for the treatment of Anastomotic Leaks (AL) or Hartmann's stump leakages following colorectal surgery in a prospective multi-center study.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Orlando Regional Medical Center, Orlando, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed grade B anastomotic leak as per the ISGRC (International Study Group of Rectal Cancer) grading system after colorectal surgery.
  • Subject is eligible for endoscopic intervention.
  • Subject has a transmural defect of at least 2 cm in diameter following colorectal surgery in the lower pelvic area.
  • Subject has an anastomotic or Hartmann's stump leak located within an extraperitoneal cavity.
  • Subject has pre-existing diverting ostomy or an ostomy created prior to the first Endo-SPONGE placement.
  • Subject understands the trial requirements and is willing and able to comply with the study procedures, all protocol-required follow up evaluations and provide written informed consent to participate in the study.
  • Investigator decision that EVT is the most suitable treatment of the available treatment options.

Exclusion criteria

  • Subject is under 18 years of age.
  • Potentially vulnerable subject, including, but not limited to pregnant women.
  • Subject has undergone EVT or other similar interventions for the current colorectal indication.
  • Subject had colorectal surgery more than 60 days prior to the planned study procedure.
  • Subject has any necrotic tissue that would require endoscopic debridement prior to Endo-SPONGE placement.
  • Subject has known contraindication for EVT as per the IB.
  • Subject is currently enrolled in another investigational study that would directly interfere with the current study, without prior written approval from the sponsor.

Treatment and study plan

Endo-SPONGE

Device

The intervention involves the placement of an Endo-SPONGE in the leakage cavity, and applying suction to facilitate drainage.

Primary outcomes

  1. Serious Adverse Events

    Time frame: Day 0 Study Procedure to end of study; up to 6 months

    The proportion of subjects with one or more study device or endoscopic or study procedure-related Serious Adverse Events (SAEs) occurring up to 3 months after the last study device removal.

  2. Clinical Success

    Time frame: Day 0 Study Procedure to the last study device removal; up to 3 months

    The proportion of subjects that demonstrate clinical success, which is defined as closure of the anastomotic or Hartmann's stump leak, confirmed via endoscopy or contrast-enhanced computed tomography imaging within 3 months after the study procedure without the need for an additional endoscopic or surgical intervention.

Secondary outcomes

  1. Technical Success

    Time frame: Day 0 Study Procedure to the last study device exchange; up to 3 months

    Defined as the ability to deploy the Endo-SPONGE in the intended location. This will be calculated for study procedure and every Endo-SPONGE Exchange that is attempted.

  2. Closure Time

    Time frame: Day 0 Study Procedure to the last study device removal; up to 3 months

    Time to colorectal anastomotic or Hartmann's stump leak closure.

  3. Rate of Reinterventions

    Time frame: From last study device removal to end of study; 3 months

    Rate of Reinterventions after closure of the anastomotic or Hartmann's stump leak.

  4. Time to Additional Intervention

    Time frame: Day 0 Study Procedure to the last study device removal; up to 3 months

    Time to additional intervention, if Endo-SPONGE treatment is insufficient.

  5. Leak Recurrence

    Time frame: From last study device removal to end of study; 3 months

    Leak recurrence within 3 months following completion of Endo-SPONGE therapy.

  6. Endo-SPONGE Exchanges

    Time frame: Day 0 Study Procedure to last study device removal; up to 3 months

    Number of Endo-SPONGE exchanges needed to reach clinical success.

  7. Length of Hospitalization

    Time frame: Day 0 Study Procedure to end of study; up to 6 months

    Length of Hospitalization.

  8. Mortality Rate

    Time frame: Day 0 Study Procedure to end of study; up to 6 months

    Mortality rate through 3-month follow-up.

Study contacts

Contact information is provided by the study sponsor or research team.

Steve Fodem

CONTACT

[email protected]

651-246-3094

Sponsors and collaborators

Lead sponsor

Boston Scientific Corporation

Industry

Registry information

Official study title

A Prospective Multicenter Trial Evaluating the Safety and Effectiveness of Endo-SPONGE for the Treatment of Anastomotic or Hartmann's Stump Leakages in the Lower Pelvic Area

Acronym: DRAIN Lower

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jun 25, 2025
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.